€ million |
|
Note |
|
2021 |
|
2020 |
|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
3,065 |
|
1,994 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Net defined benefit liability |
|
|
|
|
|
|
Changes in remeasurement |
|
|
|
751 |
|
-602 |
Tax effect |
|
|
|
-119 |
|
130 |
Changes recognized in equity |
|
|
|
632 |
|
-473 |
Equity instruments |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-41 |
|
116 |
Tax effect |
|
|
|
8 |
|
– |
Changes recognized in equity |
|
|
|
-33 |
|
116 |
|
|
|
|
599 |
|
-356 |
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-127 |
|
54 |
Reclassification to profit or loss |
|
|
|
27 |
|
45 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
5 |
|
-30 |
Changes recognized in equity |
|
|
|
-95 |
|
69 |
Cost of cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-13 |
|
-13 |
Reclassification to profit or loss |
|
|
|
27 |
|
12 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
-3 |
|
1 |
Changes recognized in equity |
|
|
|
11 |
|
-1 |
Currency translation difference |
|
|
|
|
|
|
Changes taken directly to equity |
|
|
|
1,730 |
|
-1,864 |
Reclassification to profit or loss |
|
|
|
-6 |
|
4 |
Changes recognized in equity |
|
|
|
1,724 |
|
-1,860 |
|
|
|
|
1,640 |
|
-1,792 |
Other comprehensive income |
|
|
|
2,239 |
|
-2,149 |
Comprehensive income |
|
|
|
5,304 |
|
-155 |
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
5,289 |
|
-160 |
thereof: attributable to non-controlling interests |
|
|
15 |
|
5 |